EP1586571A1 — Dipeptidyl peptidase inhibitors
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2005-10-19 · 21y expired
What this patent protects
Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising Formula I : wherein M is N or CR 4 ; Q 1 and Q 2 are each independently selected from the group consisting of CO, SO, SO 2 , and C=NR 9 ; …
USPTO Abstract
Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising Formula I : wherein M is N or CR 4 ; Q 1 and Q 2 are each independently selected from the group consisting of CO, SO, SO 2 , and C=NR 9 ; and each R 1 , R 2 , R 3 , R 4 and R 9 are as defined herein.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.